What Happened?
Milwaukee, WI-based Promentis Pharmaceuticals Appointed John Mantsch as Co founder
About the Company
Promentis Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system (CNS) disorders. Promentis` drug development program is focused on activating a unique target known to restore glutamatergic neurotransmission and imbalances in oxidative stress, key contributors to impaired cortical function linked to multiple CNS disorders. The Company`s lead compound, SXC-2023, is being developed to treat various psychiatric disorders, with an initial focus on an indication that, despite representing a common disorder affecting millions of patients, has no FDA-approved treatment and a high level of patient need.
About the Person
John Mantsch is Co founder at Promentis Pharmaceuticals. Previously, John held various senior HR leadership roles in the industry.
Info Source
News
Short Profile